TRP-2 mRNA-electroporated Langerhans-type dendritic cells

**TRP-2 mRNA-electroporated Langerhans-type dendritic cells** is an investigational cell-based cancer vaccine composed of autologous Langerhans-type dendritic cells (LCs). These cells are harvested from the patient, partially matured, and then electroporated with mRNA encoding murine tyrosinase-related protein 2 (TRP2), a melanoma-associated antigen. Once re-infused, the manipulated LCs present the TRP2 antigen to the immune system, eliciting both CD4 and CD8 T cell responses including increased pro-inflammatory cytokine secretion and cytotoxicity, thereby targeting melanoma cells expressing TRP2. The methodology avoids vector-based genetic modification and enhances antigen presentation over peptide loading, supporting robust and broad immune activation. This strategy was primarily developed and clinically evaluated at Memorial Sloan Kettering Cancer Center, with completed phase I trials in patients with resected advanced melanoma[1][3][5].

Other names

autologous Langerhans-type dendritic cells electroporated with mRNA encoding TRP2TRP2 mRNA-electroporated LCsTRP-2 mRNA-electroporated LCsTRP 2 mRNA-electroporated LCs